{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:17:50Z","timestamp":1787062670645,"version":"build-2736575974"},"reference-count":28,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2014,6,11]],"date-time":"2014-06-11T00:00:00Z","timestamp":1402444800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2014,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Dopamine agonists (DA) are often used as first\u2010line monotherapy for the symptomatic control of Parkinson's disease (PD). However, DA monotherapy typically becomes inadequate within a few years, at which time the DA dosage must be increased or other antiparkinsonian medications added. Adding a monoamine oxidase\u2010B (MAO\u2010B) inhibitor to DA monotherapy might improve symptomatic control while maintaining good safety and tolerability. We conducted an 18\u2010week, randomized, double\u2010blind, placebo\u2010controlled trial of rasagiline 1 mg\/d as an add\u2010on to DA therapy (ropinirole\u2009\u2265\u20096 mg\/d or pramipexole\u2009\u2265\u20091.0 mg\/d) in early PD patients whose conditions were not adequately controlled on their current treatment regimen. The primary efficacy variable was the change in total Unified Parkinson Disease Rating Scale (UPDRS) score (sum of parts I, II, and III) from baseline to week 18, comparing rasagiline and placebo groups. The modified intent\u2010to\u2010treat (ITT) population included 321 subjects whose mean\u2009\u00b1\u2009SD age was 62.6\u2009\u00b1\u20099.7, and duration of PD was 2.1\u2009\u00b1\u20092.1 years. Results demonstrated a significantly greater improvement in total UPDRS scores from baseline to week 18 in the rasagiline group compared with the placebo group (least squares [LS] mean difference\u2009\u00b1\u2009SE, \u22122.4\u2009\u00b1\u20090.95; 95% confidence interval [CI], \u22124.3, \u22120.5;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.012). Mean improvement (LS mean\u2009\u00b1\u2009SE) was \u22123.6\u2009\u00b1\u20090.68 in the rasagiline group and \u22121.2\u2009\u00b1\u20090.68 in the placebo group. Rasagiline was well tolerated, and the most common adverse events (AEs; rasagiline vs. placebo) were dizziness (7.4% vs. 6.1%), somnolence (6.8% vs. 6.7%), and headache (6.2% vs. 4.3%). Rasagiline 1 mg\/d provided statistically significant improvement when added to dopamine agonist therapy and was well tolerated. \u00a9 2014 International Parkinson and Movement Disorder Society\n                  <\/jats:p>","DOI":"10.1002\/mds.25877","type":"journal-article","created":{"date-parts":[[2014,6,11]],"date-time":"2014-06-11T13:28:19Z","timestamp":1402493299000},"page":"1028-1034","source":"Crossref","is-referenced-by-count":53,"title":["Randomized, controlled trial of rasagiline as an add\u2010on to dopamine agonists in Parkinson's disease"],"prefix":"10.1002","volume":"29","author":[{"given":"Robert A.","family":"Hauser","sequence":"first","affiliation":[{"name":"Parkinson's Disease and Movement Disorders Center University of South Florida Tampa Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dee","family":"Silver","sequence":"additional","affiliation":[{"name":"Coastal Neurological Medical Group La Jolla California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azhar","family":"Choudhry","sequence":"additional","affiliation":[{"name":"Teva Pharmaceuticals Kansas City Missouri USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli","family":"Eyal","sequence":"additional","affiliation":[{"name":"Teva Pharmaceutical Industries Petach Tikva Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Isaacson","sequence":"additional","affiliation":[{"name":"Parkinson's Disease and Movement Disorders Center of Boca Raton  Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the ANDANTE study investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,6,11]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.61.7.1044"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200005183422004"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70225-X"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.63.7.969"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0b013e31826e6e6d"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.63.12.1756"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25364"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrn1883"},{"key":"e_1_2_8_10_1","first-page":"153","article-title":"Unified Parkinson's Disease Rating Scale. Recent developments in Parkinson's disease","author":"Fahn S","year":"1987","journal-title":"MacMillan Healthcare Information"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005537-199603000-00021"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000091864.39702.1C"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/PL00007730"},{"key":"e_1_2_8_14_1","first-page":"218","volume-title":"Clinical global impressions. ECDEU Assessment Manual for Psychopharmacology","author":"Guy W","year":"1976"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/26.8.1049"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20914"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2009.295"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23638"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20913"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.59.12.1937"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2009.06209.x"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/syn.10049"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0702673"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.62.2.241"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)71083-7"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2013.06.001"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0060691"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1819.2012.02339.x"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25661"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.25877","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.25877","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.25877","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/mds.25877","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.25877","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T10:36:02Z","timestamp":1760956562000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.25877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,11]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["10.1002\/mds.25877"],"URL":"https:\/\/doi.org\/10.1002\/mds.25877","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,11]]}}}